New and emerging LDL cholesterol-lowering drugs

American Journal of Therapeutics

Volumn 22, Issue 3, 2015, Pages 234-241

  Kosmas, Constantine E ^a   Frishman, William H ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

atherosclerosis; cholesterol lowering drugs; LDL cholesterol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALIROCUMAB; ANACETRAPIB; APOLIPOPROTEIN B; APOLIPOPROTEIN C; ATORVASTATIN; BEMPEDOIC ACID; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CREATINE KINASE; DALCETRAPIB; EVACETRAPIB; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IMPLITAPIDE; LIVER X RECEPTOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROTEIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; WAY 252623; 2-(2-CHLORO-4-FLUOROBENZYL)-3-(4-FLUOROPHENYL)-7-(TRIFLUOROMETHYL)-2H-INDAZOLE; 8-HYDROXY-2,2,14,14-TETRAMETHYLPENTADECANEDIOIC ACID; DICARBOXYLIC ACID; FATTY ACID; INDAZOLE DERIVATIVE; OLIGONUCLEOTIDE; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY RISK; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; FLU LIKE SYNDROME; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HUMAN; INFLUENZA; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; LEUKOCYTOCLASTIC VASCULITIS; LIPOPROTEIN SYNTHESIS; LOSS OF FUNCTION MUTATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BLOOD; DOUBLE BLIND PROCEDURE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, LDL; DICARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; FATTY ACIDS; HUMANS; INDAZOLES; OLIGONUCLEOTIDES; PROPROTEIN CONVERTASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERINE ENDOPEPTIDASES;

EID: 84929511008     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000063     Document Type: Review

References (52)

1. O'Keefe JH Jr, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-2146.
2. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
3. Waters DD. What the statin trials have taught us. Am J Cardiol. 2006;98:129-134.
4. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National cholesterol Education Program Adult treatment Panel III guidelines. Circulation. 2004;110:227-239.
5. Martin SS, Gosch K, Kulkarni KR, et al. Modifiable factors associated with failure to attain low-density lipopro-tein cholesterol goal at 6 months after acute myocardial infarction. Am Heart J. 2013;165:26-33.e3.
6. Virani SS, Woodard LD, Chitwood SS, et al. Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. Am Heart J. 2011;162:725-732.e1.
7. Cohen JD, Brinton EA, Ito MK, et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10, 138 current and former statin users. J Clin Lipidol. 2012;6:208-215.
8. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-Analysis of randomised statin trials. Lancet. 2010;375:735-742.
9. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-Analysis. JAMA. 2011;305:2556-2564.
10. FDA Drug Safety Communication. Important safety label changes to cholesterol-lowering statin drugs. Available at: http://www.fda.gov/drugs/drugsafety/ucm293101.htm. Accessed February 28, 2012.
11. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Car-diol. 1998;82:35U-38U.
12. Knopp RH, Brown WV, Dujovne CA, et al. Effects of fe-nofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med. 1987;83:50-59.
13. Knopp RH, Dujovne CA, Le Beaut A, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003; 57:363-368.
14. Insull W Jr, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001;76:971-982.
15. Ricotta DN, Frishman WH. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol Rev. 2012;20:90-95.
16. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apo-lipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998-1006.
17. Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterol-emia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013;62:2178-2184.
18. Akdim F, Visser ME, Tribble DL, et al. Effect of mipo-mersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105:1413-1419.
19. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33:1142-1149.
20. Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipo-protein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011;32:2650-2659.
21. Furtado JD, Wedel MK, Sacks FM. Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins. J Lipid Res. 2012;53:784-791.
22. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1997;1345:136-150.
23. Calandra S, Tarugi P, Speedy HE, et al. Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk. J Lipid Res. 2011;52: 1885-1926.
24. Wierzbicki AS, Viljoen A, Hardman TC, et al. New therapies to reduce low-density lipoprotein cholesterol. Curr Opin Cardiol. 2013;28:452-457.
25. Wilkinson MJ, Davidson MH. Recent developments in the treatment of familial hypercholesterolemia: a review of several new drug classes. Curr Treat Options Cardiovasc Med. 2013;15:696-705.
26. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hyper-cholesterolaemia: a single-Arm, open-label, phase 3 study. Lancet. 2013;381:40-46.
27. Qian YW, Schmidt RJ, Zhang Y, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res. 2007;48: 1488-1498.
28. Weinreich M, Frishman WH. Antihyperlipidemic therapies targeting PCSK9. Cardiol Rev. 2014;22:140-146.
29. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156.
30. Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet. 2004;65:419-422.
31. Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
32. Dubuc G, Chamberland A, Wassef H, et al. Statins upre-gulate PCSK9, the gene encoding the proprotein conver-tase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004;24:1454-1459.
33. Norata GD, Ballantyne CM, Catapano AL. New therapeutic principles in dyslipidaemia: focus on LDL and Lp (a) lowering drugs. Eur Heart J. 2013;34:1783-1789.
34. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108-1118.
35. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29-36.
36. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein conver-tase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-2353.
37. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hyper-cholesterolemia. N Engl J Med. 2012;367:1891-1900.
38. Regeneron. Sanofi and Regeneron report positive top-line results with alirocumab from first phase 3 study of a PCSK9 inhibitor for LDL-cholesterol reduction [press releases]. 2013. Available at: investor.regeneron.com/releasedetail. cfm?ReleaseID5797732. Accessed October 16, 2013.
39. Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of Longer-Term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-Week results from the open-label study of Long-Term Evaluation against LDL-C (OSLER) randomized trial. Circulation. 2013;129:234-243.
40. Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-Activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54:134-151.
41. Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-Activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62:1154-1162.
42. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torce-trapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
43. Frishman WH, Barkowski RS. Cholesteryl ester transfer protein inhibition for coronary heart disease prevention: real hope or despair? Am J Med. 2008;121:644-646.
44. Kosmas CE, Christodoulidis G, Cheng JW, et al. High-density lipoprotein Functionality in coronary artery disease. Am J Med Sci. 2014;347:504-508.
45. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalce-trapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-2099.
46. Cannon CP, Shah S, Dansky HM, et al. Safety of anace-trapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406-2415.
47. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306:2099-2109.
48. Parikh N, Frishman WH. Liver X receptors: a potential therapeutic target for modulating the atherosclerotic process. Cardiol Rev. 2010;18:269-274.
49. Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes Dev. 2000;14:2831-2838.
50. Peet DJ, Turley SD, Ma W, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell. 1998;93:693-704.
51. Bradley MN, Hong C, Chen M, et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest. 2007;117:2337-2346.
52. Quinet EM, Basso MD, Halpern AR, et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res. 2009;50:2358-2370.